SCHEMBL9415751

SCHEMBL9415751

O=C(CCCCC(=O)N1CCOCC1)N1CCOCC1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GLA P06280 1/20 0.67
L3MBTL1 Q9Y468 4/20 0.61
RAB9A P51151 3/20 0.61
LMNA P02545 2/20 0.56
TSHR P16473 2/20 0.56
POLB P06746 2/20 0.56
ATM Q13315 1/20 0.56
ALDH1A1 P00352 2/20 0.55
FKBP1A P62942 1/20 0.55
USP2 O75604 2/20 0.54
CYP1A2 P05177 1/20 0.54
CYP3A4 P08684 1/20 0.54
CYP2C9 P11712 1/20 0.54
CYP2C19 P33261 1/20 0.54
ALOX15 P16050 1/20 0.54
HSD17B10 Q99714 1/20 0.54
TDP1 Q9NUW8 2/20 0.50
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
NPC1 O15118 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7694058 0.98 GLA (0.65) GLAL3MBTL1RAB9ALMNATSHR
SCHEMBL5452859 0.92 GLA (0.59) GLAL3MBTL1RAB9ALMNATSHR
SCHEMBL2952110 0.92 GLA (0.59) GLAL3MBTL1RAB9ALMNATSHR
SCHEMBL6043811 0.92 GLA (0.59) GLAL3MBTL1RAB9ALMNATSHR
SCHEMBL11536082 0.90 GLA (0.57) GLAL3MBTL1RAB9ALMNATSHR
SCHEMBL9113643 0.90 GLA (0.57) GLAL3MBTL1RAB9ALMNATSHR
SCHEMBL2718359 0.90 L3MBTL1 (0.69) GLAL3MBTL1RAB9ALMNATSHR
SCHEMBL9113633 0.90 GLA (0.57) GLAL3MBTL1RAB9ALMNATSHR
SCHEMBL9160397 0.90 GLA (0.57) GLAL3MBTL1RAB9ALMNATSHR
SCHEMBL293472 0.90 GLA (0.57) GLAL3MBTL1RAB9ALMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250195409-A1 METHODS FOR IMPROVING CUTANEOUS PERMEATION OF CANNABINOIDS AND FATTY ACID AMIDES Ananda Scientific, Inc. (US) 2025-06-19 US disclosed
EP-0582065-A1 1-Oxohydrocarbyl-substituted azacyclohexanes compositions used as acid catalyst WHITBY RESEARCH, Inc. (US) 1994-02-09 EP disclosed
EP-0280703-B1 COMPOSITIONS COMPRISING 1-ACYL-SUBSTITUTED MORPHOLINES, THIOMORPHOLINES AND PIPERAZINES AND THEIR USES WHITBY RESEARCH INC (US) 1993-12-29 EP disclosed
US-5073544-A Penetration promoters WHITBY, INC. (US) 1991-12-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250195409-A1 METHODS FOR IMPROVING CUTANEOUS PERMEATION OF CANNABINOIDS AND FATTY ACID AMIDES CNR2, CNR1, FAAH GLA 3055/4885L3MBTL1 4862/4885RAB9A 3043/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.